File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Diagnosis and management of natural killer-cell malignancies

TitleDiagnosis and management of natural killer-cell malignancies
Authors
Issue Date2010
Citation
Expert Review Of Hematology, 2010, v. 3 n. 5, p. 593-602 How to Cite?
AbstractNatural killer (NK)-cell malignancies are uncommon neoplasms, which have been referred to as polymorphic reticulosis or angiocentric T-cell lymphomas in the past. In the current WHO classification, they are categorized as extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia. NK-cell malignancies show a geographical predilection for Asian and South American populations and are rare in the west. Pathologically, NK-cell lymphomas show a polymorphic neoplastic infiltrate with angioinvasion and angiodestruction. The lymphoma cells are CD2+, cytoplasmic CD3+ and CD56 +, with germline T-cell receptor gene. There is an almost invariable clonal episomal infection with Epstein-Barr virus. Clinically, NK-cell lymphomas can be classified into nasal, non-nasal and aggressive lymphoma/leukemia subtypes. Most nasal NK-cell lymphomas present with stage I/II disease. The early use of radiotherapy, either alone or concomitantly/sequentially with chemotherapy, is the most important factor in achieving successful treatment. Many stage I/II patients receiving radiotherapy alone fail systemically, so the use of chemotherapy is also considered necessary. Chemotherapy is indicated for stage III/IV nasal NK-cell lymphoma, and the non-nasal and aggressive subtypes. Recent regimens that incorporate the use of L-asparaginase have resulted in substantial improvements in outcome in high-risk, refractory or relapsed patients. High-dose chemotherapy and hematopoietic stem-cell transplantation with autologous or allogeneic hematopoietic stem cells may be beneficial to selected patients. Prognostication of patients with clinical prognostic models and presentation circulating Epstein-Barr DNA load may be useful in the stratification of patients for various treatment modalities. © 2010 Expert Reviews Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163342
ISSN
2015 Impact Factor: 2.439
2015 SCImago Journal Rankings: 1.059
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorIshida, Fen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:30:19Z-
dc.date.available2012-09-05T05:30:19Z-
dc.date.issued2010en_US
dc.identifier.citationExpert Review Of Hematology, 2010, v. 3 n. 5, p. 593-602en_US
dc.identifier.issn1747-4086en_US
dc.identifier.urihttp://hdl.handle.net/10722/163342-
dc.description.abstractNatural killer (NK)-cell malignancies are uncommon neoplasms, which have been referred to as polymorphic reticulosis or angiocentric T-cell lymphomas in the past. In the current WHO classification, they are categorized as extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia. NK-cell malignancies show a geographical predilection for Asian and South American populations and are rare in the west. Pathologically, NK-cell lymphomas show a polymorphic neoplastic infiltrate with angioinvasion and angiodestruction. The lymphoma cells are CD2+, cytoplasmic CD3+ and CD56 +, with germline T-cell receptor gene. There is an almost invariable clonal episomal infection with Epstein-Barr virus. Clinically, NK-cell lymphomas can be classified into nasal, non-nasal and aggressive lymphoma/leukemia subtypes. Most nasal NK-cell lymphomas present with stage I/II disease. The early use of radiotherapy, either alone or concomitantly/sequentially with chemotherapy, is the most important factor in achieving successful treatment. Many stage I/II patients receiving radiotherapy alone fail systemically, so the use of chemotherapy is also considered necessary. Chemotherapy is indicated for stage III/IV nasal NK-cell lymphoma, and the non-nasal and aggressive subtypes. Recent regimens that incorporate the use of L-asparaginase have resulted in substantial improvements in outcome in high-risk, refractory or relapsed patients. High-dose chemotherapy and hematopoietic stem-cell transplantation with autologous or allogeneic hematopoietic stem cells may be beneficial to selected patients. Prognostication of patients with clinical prognostic models and presentation circulating Epstein-Barr DNA load may be useful in the stratification of patients for various treatment modalities. © 2010 Expert Reviews Ltd.en_US
dc.languageengen_US
dc.relation.ispartofExpert Review of Hematologyen_US
dc.subject.meshAntigens, Cden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAsia - Epidemiologyen_US
dc.subject.meshAsparaginase - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHematopoietic Stem Cell Transplantationen_US
dc.subject.meshHerpesvirus 4, Humanen_US
dc.subject.meshHumansen_US
dc.subject.meshKiller Cells, Natural - Drug Effects - Pathologyen_US
dc.subject.meshLeukemia - Diagnosis - Mortality - Pathology - Therapyen_US
dc.subject.meshLymphoma, Extranodal Nk-T-Cell - Diagnosis - Mortality - Pathology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshSeverity Of Illness Indexen_US
dc.subject.meshSouth America - Epidemiologyen_US
dc.subject.meshTransplantation, Autologousen_US
dc.titleDiagnosis and management of natural killer-cell malignanciesen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1586/ehm.10.51en_US
dc.identifier.pmid21083476-
dc.identifier.scopuseid_2-s2.0-78049436912en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78049436912&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume3en_US
dc.identifier.issue5en_US
dc.identifier.spage593en_US
dc.identifier.epage602en_US
dc.identifier.isiWOS:000284746200013-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridIshida, F=35399907400en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats